First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Medline: the story is balanced — Hospital procedure volumes and surgical case growth—drives demand for disposable supplies, gowns, and surgical kits
★ Analysts see FY2026 revenue reaching $31.1B — +9.3% growth in a single year.
What Moves the Stock
1Hospital procedure volumes and surgical case growth—drives demand for disposable supplies, gowns, and surgical kits
2GPO (Group Purchasing Organization) contract wins and renewals—large multi-year agreements with Premier, Vizient, HealthTrust can shift $500M+ in annual revenue
3Raw material costs, particularly resin prices for gloves and petroleum-based plastics—directly impacts gross margins on manufactured products
4Healthcare labor shortages and hospital staffing levels—affects utilization rates and elective procedure scheduling
5Medicare reimbursement rate changes and hospital capital spending—influences customer purchasing budgets and payment terms
6Medical-surgical product distribution (~65-70% of revenue): disposable gloves, gowns, drapes, surgical kits to acute care facilities
value - The 2.6x P/S and 31.5x EV/EBITDA multiples reflect private equity ownership structure with limited public float.
Rising rates have moderate negative impact through two channels: (1) Higher financing costs on the $18B debt load (0.97 D/E ratio) as debt…
Watch on earnings: AHA hospital admissions data and surgical procedure volumes (leading indicator for demand), Resin and crude oil prices (DCOILWTICO)—primary input cost for disposable gloves, plastic products, Healthcare employment trends (PAYEMS healthcare subsector)—proxy for hospital staffing levels and utilization.
One Sentence Summary:
Medline: the story is balanced — hospital procedure volumes and surgical case growth—drives demand for disposable supplies, gowns, and surgical kits.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.